Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Endocrine 2

Conditions

Neuroendocrine Tumors 4Differentiated Thyroid Cancer 2Adenoma, Islet Cell 2Tuberous Sclerosis 1Thyroid Cancer, Papillary 1Pituitary Neoplasms 1Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Insulinoma 1Hyperinsulinism 1Growth Hormone-Secreting Pituitary Adenoma 1Gastroenteropancreatic Neuroendocrine Tumors 1Congenital Hyperinsulinism 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1Advanced Extrapulmonary Neuroendocrine Cancer 1Adenocarcinoma, Follicular 1Acromegaly 1

Interventions

Thyrotropin Alfa 4donafenib 2Injections 2vandetanib 1surufatinib 1pembrolizumab 1lenvatinib 1apatinib 1anlotinib 1Sorafenib 1Iodine-131 1Everolimus 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Differentiated Thyroid Cancer × Injections × Endocrine × Clear all
NCT04137185 2024-03-06

Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1/2 Completed
64 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT04447183 2023-10-23

DTC

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 2 Unknown
120 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡